Pulse Biosciences, Inc. (PLSE) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Pulse Biosciences is a bioelectric medicine company developing Nano-pulse Stimulation (NPS) technology for medical applications. The company has shifted its strategic focus from dermatology to cardiology (specifically atrial fibrillation) and soft tissue ablation. As of the reporting date, the company has no material cash flows from operations and continues to rely on external financing to fund research and development.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenues | $0 | $0 | $0 | $0 |
| Net Loss | $(12.68) million | $(10.57) million | $(34.20) million | $(30.28) million |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.19) | $(0.60) | $(0.64) |
| Operating Expenses | $13.66 million | $11.25 million | $36.00 million | $31.04 million |
| Cash and Cash Equivalents (End of Period) | $79.03 million (as of Sept 30, 2024) | |||
| Net Cash Used in Operating Activities (YTD) | ||||
| Net Cash Provided by Financing Activities (YTD) | $61.94 million (YTD 2024) | |||
| Total Liabilities | $13.92 million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Financing Activity: The most significant change was the completion of a 2024 Rights Offering in July 2024, raising approximately $60 million in gross proceeds. This was primarily subscribed by majority stockholder Robert W. Duggan (approx. 88%). This influx of capital increased cash balances from $44.4 million (Dec 31, 2023) to $79.0 million (Sept 30, 2024).
- Expense Growth: Operating expenses increased by $2.4 million in Q3 2024 compared to Q3 2023. General and Administrative (G&A) expenses rose by $2.2 million, driven largely by a $1.1 million increase in stock-based compensation. Research and Development (R&D) expenses increased by $0.2 million.
- Interest Income: Net interest income increased to $0.98 million in Q3 2024 from $0.69 million in Q3 2023, reflecting higher returns on increased cash balances.
- Debt Extinguishment: The company had no interest expense in the current period, as the $65 million related-party loan from 2022 was fully extinguished via equity conversion in May 2023.
Guidance, Outlook, and Risks
- Product Development:
- Soft Tissue: Received FDA 510(k) clearance for the CellFX nsPFA Percutaneous Electrode System in March 2024. A pivotal clinical trial for benign thyroid nodules is expected to commence in mid-2025.
- Cardiology: Received FDA Breakthrough Device Designation for the CellFX nsPFA Cardiac Surgery System. A pivotal clinical trial for atrial fibrillation is expected to begin in mid-2025. The CellFX nsPFA 360° Cardiac Catheter study is nearly fully enrolled.
- Liquidity Outlook: Management believes current cash resources ($79.0 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur losses for the foreseeable future and will require additional capital to complete development and commercialization.
- Stock-Based Compensation Adjustment: In October 2024 (subsequent event), the Board modified vesting conditions for certain stock options, changing performance-based criteria to time-based or market-based. This is estimated to result in approximately $12 million of additional stock-based compensation expense recognized over the next 1 to 4 years.
- Risks: Key risks include the need for additional financing, failure to obtain regulatory approvals for cardiac products, intense competition in the ablation market, and reliance on a single platform technology (NPS).
Investor Verification Checklist
- Verify the timeline and enrollment status of the pivotal clinical trials for the Cardiac Clamp and Cardiac Catheter, scheduled for mid-2025.
- Monitor the impact of the October 2024 stock option modification on future quarterly expenses (estimated $12M over 1-4 years).
- Assess the commercialization progress of the cleared Percutaneous Electrode System, specifically the number of sites and procedures performed.
- Review the concentration of ownership, noting that Robert W. Duggan owns approximately 73% of outstanding shares and subscribed to 88% of the recent rights offering.
- Confirm the company's ability to raise further capital if the $79 million cash balance is depleted before commercial revenue is generated.